Vulvar Cancer - Pipeline Review, H2 2017

Publisher Name :
Date: 30-Nov-2017
No. of pages: 92
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H2 2017, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape.

Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vulvar Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 4 and 1 respectively.

Vulvar Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vulvar Cancer (Oncology).

  • The pipeline guide reviews pipeline therapeutics for Vulvar Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Vulvar Cancer (Oncology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Vulvar Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Vulvar Cancer (Oncology)


Reasons to buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Vulvar Cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Vulvar Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Vulvar Cancer - Pipeline Review, H2 2017

Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Vulvar Cancer - Overview 5
Vulvar Cancer - Therapeutics Development 6
Pipeline Overview 6
Pipeline by Companies 7
Products under Development by Companies 8
Vulvar Cancer - Therapeutics Assessment 9
Assessment by Target 9
Assessment by Mechanism of Action 11
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Vulvar Cancer - Companies Involved in Therapeutics Development 17
Cutanea Life Sciences Inc 17
ISA Pharmaceuticals BV 17
MedImmune LLC 17
Ono Pharmaceutical Co Ltd 18
Oryx GmbH & Co KG 18
Vulvar Cancer - Drug Profiles 19
durvalumab + tremelimumab - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
ISA-101 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
nivolumab - Drug Profile 31
R&D Progress 32
omiganan pentahydrochloride - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Vicoryx - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Vulvar Cancer - Dormant Projects 88
Vulvar Cancer - Product Development Milestones 89
Featured News & Press Releases 89
Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP 89
Mar 07, 2011: ISA Pharma Receives €2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine 89
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 89
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables

Number of Products under Development for Vulvar Cancer, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Products under Development by Companies, H2 2017 8
Number of Products by Stage and Target, H2 2017 10
Number of Products by Stage and Mechanism of Action, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 14
Number of Products by Stage and Molecule Type, H2 2017 16
Vulvar Cancer - Pipeline by Cutanea Life Sciences Inc, H2 2017 17
Vulvar Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017 17
Vulvar Cancer - Pipeline by MedImmune LLC, H2 2017 18
Vulvar Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 18
Vulvar Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017 18
Vulvar Cancer - Dormant Projects, H2 2017 88

List of Figures

Number of Products under Development for Vulvar Cancer, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Number of Products by Targets, H2 2017 9
Number of Products by Stage and Targets, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 11
Number of Products by Routes of Administration, H2 2017 13
Number of Products by Stage and Routes of Administration, H2 2017 13
Number of Products by Molecule Types, H2 2017 15
Number of Products by Stage and Molecule Types, H2 2017 15

  • Global Circulating Tumor Cells Market Professional Survey Report 2018
    Published: 18-Apr-2018        Price: US 3500 Onwards        Pages: 110
    This report studies Circulating Tumor Cells in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Janssen - Qiagen(Adnagen) - Acousys Biodevices - ApoCell......
  • Global Melanoma Therapeutics Market Size, Status and Forecast 2025
    Published: 05-Apr-2018        Price: US 3300 Onwards        Pages: 98
    This report studies the global Melanoma Therapeutics market, analyzes and researches the Melanoma Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - AstraZeneca - Amgen, Inc. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Novartis AG - Merck & Co., Inc. - Daiichi Sankyo Company, Limited - AB Sciences ......
  • Global Prostate Cancer Testing Market 2018-2022
    Published: 04-Apr-2018        Price: US 3500 Onwards        Pages: 134
    About Prostate Cancer Testing Prostate cancer testing refers to the tests conducted for the detection, localization, grading, and staging of prostate carcinoma. The currently established methods of prostate cancer detection include digital rectal examination (DRE), serum prostate-specific antigen (PSA) tests, and transrectal ultrasound (TRUS)-guided prostate biopsy using a systematic 12-core method. The analysts forecast global prostate cancer testing market to grow......
  • United States Circulating Tumor Cells Market Report 2018
    Published: 27-Mar-2018        Price: US 3800 Onwards        Pages: 110
    In this report, the United States Circulating Tumor Cells market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and......
  • Global Glioblastoma Multiforme Treatment Market Size, Status and Forecast 2025
    Published: 22-Mar-2018        Price: US 3300 Onwards        Pages: 90
    This report studies the global Glioblastoma Multiforme Treatment market, analyzes and researches the Glioblastoma Multiforme Treatment development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - AbbVie, Inc - Activartis GmbH - Agenus Inc - Arog Pharmaceuticals, Inc - Bristol-Myers Squibb Company - Cavion LLC - Celldex Therapeutics Inc - Cortice......
  • Global Bladder Cancer Therapeutics Market Size, Status and Forecast 2025
    Published: 21-Mar-2018        Price: US 3300 Onwards        Pages: 97
    This report studies the global Bladder Cancer Therapeutics market, analyzes and researches the Bladder Cancer Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Pfizer - F. Hoffman-La Roche - Eli Lilly - Bristol-Myers Squibb - Merck - Sanofi - AstraZeneca - Bedford Lab - Accord Healthcare Market segme......
  • Global Circulating Tumor Cells Market Research Report 2018
    Published: 16-Mar-2018        Price: US 2900 Onwards        Pages: 118
    In this report, the global Circulating Tumor Cells market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Circulating Tumor Cells in these regions, from 2013 to 2025 (forecast), covering - North America - Europe - Ch......
  • Global Circulating Tumor Cells Sales Market Report 2018
    Published: 14-Mar-2018        Price: US 4000 Onwards        Pages: 119
    In this report, the global Circulating Tumor Cells market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Circulating Tumor Cells for these regions, from 2013 to 2025 (forecast), covering - United States - China - Europe......
  • Global Kaposi Sarcoma Market Size, Status and Forecast 2025
    Published: 07-Mar-2018        Price: US 3300 Onwards        Pages: 91
    This report studies the global Kaposi Sarcoma market, analyzes and researches the Kaposi Sarcoma development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Merck - Pfizer - Johnson & Johnson - GlaxoSmithKline - Bristol-Myers Squibb - Eli Lilly Market segment by Regions/Countries, this report covers - United States - EU - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs